Including Quality of Life as an Important End Point in Evaluating Intensive and Prolonged Treatment for Acute Myeloid Leukemia (AML)

Intensification of treatment for AML resulted in a substantial improvement in longterm prognosis (Buchner 1997). As intensive therapy might be associated with high morbidity and most patients with AML eventually relapse, quality of life (QL) of patients has become an important parameter to be assessed. This study was designed to evaluate QL in patients with AML treated according to the protocol of the German AML-Cooperative Group.